{"id":315919,"date":"2025-07-19T11:47:48","date_gmt":"2025-07-19T11:47:48","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/is-pfizer-a-good-stock-to-buy-2\/"},"modified":"2025-07-19T11:47:48","modified_gmt":"2025-07-19T11:47:48","slug":"is-pfizer-a-good-stock-to-buy","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/","title":{"rendered":"Pfizer Hisse Senedi Almak \u0130\u00e7in \u0130yi mi: Yat\u0131r\u0131m G\u00f6r\u00fcn\u00fcm\u00fc"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\"><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":307480,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[17],"tags":[28,45,44],"class_list":["post-315919","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-learning","tag-investment","tag-stock","tag-strategy"],"acf":{"h1":"Analiz: Pfizer Almak \u0130\u00e7in \u0130yi Bir Hisse Senedi mi?","h1_source":{"label":"H1","type":"text","formatted_value":"Analiz: Pfizer Almak \u0130\u00e7in \u0130yi Bir Hisse Senedi mi?"},"description":"Pfizer'in iyi bir hisse senedi olup olmad\u0131\u011f\u0131n\u0131 kapsaml\u0131 finansal metrikler, b\u00fcy\u00fcme beklentileri ve risk de\u011ferlendirmesi ile analiz etmek. Pocket Option, stratejik yat\u0131r\u0131m kararlar\u0131 i\u00e7in de\u011ferli bilgiler sunar.","description_source":{"label":"Description","type":"textarea","formatted_value":"Pfizer'in iyi bir hisse senedi olup olmad\u0131\u011f\u0131n\u0131 kapsaml\u0131 finansal metrikler, b\u00fcy\u00fcme beklentileri ve risk de\u011ferlendirmesi ile analiz etmek. Pocket Option, stratejik yat\u0131r\u0131m kararlar\u0131 i\u00e7in de\u011ferli bilgiler sunar."},"intro":"Pfizer gibi ila\u00e7 devlerini de\u011ferlendirmek, finansal g\u00fc\u00e7, pipeline potansiyeli, pazar konumu ve end\u00fcstri trendlerini dikkate alan \u00e7ok y\u00f6nl\u00fc bir yakla\u015f\u0131m gerektirir. Bu analiz, Pfizer'\u0131n yat\u0131r\u0131m durumunu derinlemesine inceleyerek, bu ila\u00e7 devini d\u00fc\u015f\u00fcnen hem yeni ba\u015flayan hem de deneyimli yat\u0131r\u0131mc\u0131lar i\u00e7in uygulanabilir i\u00e7g\u00f6r\u00fcler sunar.","intro_source":{"label":"Intro","type":"text","formatted_value":"Pfizer gibi ila\u00e7 devlerini de\u011ferlendirmek, finansal g\u00fc\u00e7, pipeline potansiyeli, pazar konumu ve end\u00fcstri trendlerini dikkate alan \u00e7ok y\u00f6nl\u00fc bir yakla\u015f\u0131m gerektirir. Bu analiz, Pfizer'\u0131n yat\u0131r\u0131m durumunu derinlemesine inceleyerek, bu ila\u00e7 devini d\u00fc\u015f\u00fcnen hem yeni ba\u015flayan hem de deneyimli yat\u0131r\u0131mc\u0131lar i\u00e7in uygulanabilir i\u00e7g\u00f6r\u00fcler sunar."},"body_html":"<div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Pfizer'\u0131n Finansal Sa\u011fl\u0131\u011f\u0131n\u0131 \u00c7\u00f6z\u00fcmleme: Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Anahtar Metrikler<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Yat\u0131r\u0131mc\u0131lar \"Pfizer iyi bir hisse senedi mi\" diye sordu\u011funda, \u015firketin sa\u011flam finansal temellerini incelemelidirler. Pfizer, en son raporlama d\u00f6nemine g\u00f6re 2.4x bor\u00e7-EBITDA oran\u0131 ve 15.4 milyar dolar nakit rezervi ile COVID-19 a\u015f\u0131 gelir art\u0131\u015f\u0131n\u0131n \u00f6tesinde finansal istikrar sergiliyor.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pfizer'\u0131n %4.7 temett\u00fc getirisi, %2.8 olan ila\u00e7 sekt\u00f6r\u00fc ortalamas\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde a\u015farak de\u011fer yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in \u00e7ekici bir giri\u015f noktas\u0131 olu\u015fturuyor. 12 y\u0131l \u00fcst \u00fcste temett\u00fcleri art\u0131ran Pfizer, piyasa dalgalanmalar\u0131 s\u0131ras\u0131nda \"Pfizer hissesi almal\u0131 m\u0131y\u0131m\" diye d\u00fc\u015f\u00fcnenler i\u00e7in cazip nedenler sunuyor.<\/p><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>Finansal Metrik<\/th><th>Pfizer Performans\u0131<\/th><th>Sekt\u00f6r Ortalamas\u0131<\/th><\/tr><\/thead><tbody><tr><td>Temett\u00fc Getirisi<\/td><td>%4.7<\/td><td>%2.8<\/td><\/tr><tr><td>F\/K Oran\u0131<\/td><td>12.3<\/td><td>16.8<\/td><\/tr><tr><td>Bor\u00e7-EBITDA<\/td><td>2.4x<\/td><td>3.1x<\/td><\/tr><tr><td>Nakit Rezervleri<\/td><td>15.4 milyar dolar<\/td><td>8.6 milyar dolar<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Pipeline Potansiyeli: Gelecek B\u00fcy\u00fcme Kataliz\u00f6rleri<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pfizer'\u0131n \u015fu anda iyi bir hisse senedi olup olmad\u0131\u011f\u0131n\u0131 belirlemede kritik bir fakt\u00f6r, \u00fcr\u00fcn pipeline'\u0131d\u0131r. Pfizer, 24'\u00fc ileri a\u015fama denemelerde olan 89 bile\u015fik geli\u015ftirmektedir. \u00c7oklu miyelom i\u00e7in elranatamab ve diyabet i\u00e7in danuglipron gibi anahtar adaylar, \u00e7ok milyar dolarl\u0131k pazarlar\u0131 hedefliyor.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pocket Option kullanarak hisse senedi analizi yapan yat\u0131r\u0131mc\u0131lar, Pfizer'\u0131n onkoloji portf\u00f6y\u00fcn\u00fc d\u00f6rt pazarlanm\u0131\u015f kanser tedavisi ile g\u00fc\u00e7lendiren Seagen'in 43 milyar dolarl\u0131k sat\u0131n al\u0131m\u0131n\u0131 not etmelidir. Bu stratejik hamle, 2027-2030 patent u\u00e7urumu s\u0131ras\u0131nda, mevcut gelirin %26's\u0131n\u0131 temsil eden ila\u00e7lar\u0131n m\u00fcnhas\u0131rl\u0131\u011f\u0131n\u0131 kaybedece\u011fi d\u00f6nemi do\u011frudan ele al\u0131yor.<\/p><\/div><div class='po-container po-container_width_article-sm'><h3 class='po-article-page__title'>B\u00fcy\u00fcme Y\u00f6r\u00fcngesini Yeniden \u015eekillendiren Stratejik Sat\u0131n Al\u0131mlar<\/h3><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>Son Sat\u0131n Alma<\/th><th>Terap\u00f6tik Odak<\/th><th>Gelir Potansiyeli<\/th><\/tr><\/thead><tbody><tr><td>Seagen (2023)<\/td><td>Onkoloji<\/td><td>2030'a kadar 10+ milyar dolar<\/td><\/tr><tr><td>Arena Pharmaceuticals<\/td><td>\u0130mm\u00fcnoloji<\/td><td>2028'e kadar 3-5 milyar dolar<\/td><\/tr><tr><td>ReViral<\/td><td>Solunum Hastal\u0131\u011f\u0131<\/td><td>2027'ye kadar 1-2 milyar dolar<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Ana Rakiplere Kar\u015f\u0131 Rekabet\u00e7i Konum<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pfizer'\u0131n Johnson &amp; Johnson, Merck ve Novartis'e kar\u015f\u0131 konumunu anlamak, Pfizer'\u0131n iyi bir hisse senedi olup olmad\u0131\u011f\u0131n\u0131 de\u011ferlendirirken \u00f6nemli bir ba\u011flam sa\u011flar. J&amp;J daha fazla \u00e7e\u015fitlilik sunarken ve Merck daha g\u00fc\u00e7l\u00fc son b\u00fcy\u00fcme oranlar\u0131 g\u00f6sterirken, Pfizer'\u0131n %22 onkoloji CAGR'si, %14 olan sekt\u00f6r ortalamas\u0131n\u0131 a\u015f\u0131yor.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pocket Option analiz ara\u00e7lar\u0131, Pfizer'\u0131n %19 i\u015fletme marj\u0131n\u0131n, %15 olan ila\u00e7 sekt\u00f6r\u00fc ortalamas\u0131n\u0131 a\u015ft\u0131\u011f\u0131n\u0131 ve geliri k\u00e2ra d\u00f6n\u00fc\u015ft\u00fcrmede verimlili\u011fi g\u00f6sterdi\u011fini ortaya koyuyor. \"Pfizer hissesini satmal\u0131 m\u0131y\u0131m\" diye soran yat\u0131r\u0131mc\u0131lar, \u015firketin 2008-2009 resesyonu s\u0131ras\u0131nda, daha geni\u015f piyasa %38 d\u00fc\u015ferken, istikrarl\u0131 gelir sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6z \u00f6n\u00fcnde bulundurmal\u0131d\u0131r.<\/p><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Risk De\u011ferlendirmesi: Patent U\u00e7urumlar\u0131 ve Azaltma Stratejileri<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pfizer'\u0131n \u015fu anda iyi bir hisse senedi olup olmad\u0131\u011f\u0131n\u0131 d\u00fc\u015f\u00fcnenler i\u00e7in, Eliquis (5.6 milyar dolar gelir), Xtandi (1.2 milyar dolar) ve Ibrance (5.4 milyar dolar) i\u00e7in 2026-2029 patent s\u00fcrelerinin dolmas\u0131 \u00f6nemli zorluklar te\u015fkil ediyor. Ancak, Pfizer, 2011'deki Lipitor patent kayb\u0131n\u0131 (13 milyar dolar zirve sat\u0131\u015flar\u0131) maliyetleri %25 azaltarak ve 24 ay i\u00e7inde be\u015f yeni ila\u00e7 onay\u0131n\u0131 h\u0131zland\u0131rarak ba\u015far\u0131yla atlatt\u0131.<\/p><\/div><div class='po-container po-container_width_article-sm article-content po-article-page__text'><ul class='po-article-page-list'><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Pipeline de\u011fi\u015ftirme potansiyeli: 2026'dan \u00f6nce planlanan 15 yeni ila\u00e7 ba\u015fvurusu<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>2025-2027 i\u00e7in stratejik sat\u0131n al\u0131mlar i\u00e7in 25 milyar dolar b\u00fct\u00e7e<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Asya-Pasifik'te co\u011frafi geni\u015fleme, geli\u015fmekte olan pazarlarda %18 b\u00fcy\u00fcme hedefliyor<\/li><\/ul><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>Risk Fakt\u00f6r\u00fc<\/th><th>Potansiyel Gelir Etkisi<\/th><th>Azaltma Stratejisi<\/th><\/tr><\/thead><tbody><tr><td>Eliquis Patenti (2026)<\/td><td>Y\u0131ll\u0131k -5.6 milyar dolar<\/td><td>Oral PCSK9 lansman\u0131 (2025)<\/td><\/tr><tr><td>ABD Fiyatland\u0131rma Mevzuat\u0131<\/td><td>%8 marj s\u0131k\u0131\u015fmas\u0131<\/td><td>3 milyar dolarl\u0131k maliyet yeniden yap\u0131land\u0131rma program\u0131<\/td><\/tr><tr><td>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/td><td>Programa g\u00f6re de\u011fi\u015fir<\/td><td>Geli\u015ftirilmekte olan 89 bile\u015fik<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>De\u011ferleme Analizi: Fiyat vs. Potansiyel<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Mevcut de\u011ferleme metrikleri, Pfizer'\u0131n 12.3x F\/K oran\u0131nda i\u015flem g\u00f6rd\u00fc\u011f\u00fcn\u00fc, hem 10 y\u0131ll\u0131k tarihsel ortalamas\u0131n\u0131n (14.8x) hem de ila\u00e7 sekt\u00f6r\u00fc ortalamas\u0131n\u0131n (16.8x) alt\u0131nda oldu\u011funu g\u00f6steriyor. Yat\u0131r\u0131mc\u0131lar \"Pfizer iyi bir hisse mi\" diye Pocket Option kullanarak de\u011ferlendirdi\u011finde, bu indirim, pipeline varl\u0131klar\u0131n\u0131n beklenen sonu\u00e7lar\u0131 vermesi durumunda potansiyel bir d\u00fc\u015f\u00fck de\u011ferleme oldu\u011funu g\u00f6steriyor.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>15.4 milyar dolar nakit ve y\u0131l\u0131n tamam\u0131 i\u00e7in projeksiyon edilen 23 milyar dolar serbest nakit ak\u0131\u015f\u0131 ile Pfizer, hem %4.7 temett\u00fc getirisini hem de planlanan 25 milyar dolarl\u0131k stratejik sat\u0131n al\u0131mlar\u0131 desteklemek i\u00e7in finansal esnekli\u011fe sahiptir. Bu g\u00fc\u00e7l\u00fc sermaye pozisyonu, hissedar de\u011feri yaratmak i\u00e7in birden fazla yol sunar.<\/p><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Yat\u0131r\u0131m Stratejisi: Farkl\u0131 Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in \u00d6zelle\u015ftirilmi\u015f Yakla\u015f\u0131mlar<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>\"Pfizer hissesi almal\u0131 m\u0131y\u0131m\" sorusunun yan\u0131t\u0131, yat\u0131r\u0131m hedeflerinize ba\u011fl\u0131 olarak farkl\u0131l\u0131k g\u00f6sterir. Gelir yat\u0131r\u0131mc\u0131lar\u0131, Pfizer'\u0131n %4.7 temett\u00fc getirisi ve %53 \u00f6deme oran\u0131ndan faydalanarak temett\u00fc s\u00fcrd\u00fcr\u00fclebilirli\u011fini \u00f6nerir. B\u00fcy\u00fcme odakl\u0131 yat\u0131r\u0131mc\u0131lar, \u00f6n\u00fcm\u00fczdeki pipeline kataliz\u00f6rlerine, \u00f6n\u00fcm\u00fczdeki 18 ayda planlanan 5 ila\u00e7 lansman\u0131na odaklanmal\u0131d\u0131r.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pocket Option, yat\u0131r\u0131mc\u0131lar\u0131n Pfizer pozisyonlar\u0131n\u0131 risk toleranslar\u0131 ve zaman ufuklar\u0131 ile uyumlu hale getirmelerine olanak tan\u0131yan ara\u00e7lar sunar. Muhafazakar yat\u0131r\u0131mc\u0131lar, Pfizer'\u0131n pipeline ge\u00e7i\u015fi boyunca dolar-maliyet ortalamas\u0131 yapmay\u0131 d\u00fc\u015f\u00fcnebilirken, daha y\u00fcksek risk tolerans\u0131na sahip olanlar, b\u00fcy\u00fck klinik veri a\u00e7\u0131klamalar\u0131 \u00f6ncesinde stratejik olarak pozisyonlar\u0131n\u0131 art\u0131rabilirler.<\/p><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>Yat\u0131r\u0131mc\u0131 Profili<\/th><th>Optimal Pfizer Stratejisi<\/th><th>Anahtar Performans G\u00f6stergesi<\/th><\/tr><\/thead><tbody><tr><td>Gelir Odakl\u0131<\/td><td>Uzun vadeli tutma<\/td><td>Temett\u00fc b\u00fcy\u00fcme oran\u0131 (%5.3)<\/td><\/tr><tr><td>De\u011fer Odakl\u0131<\/td><td>Zay\u0131fl\u0131kta biriktirme<\/td><td>F\/K vs. tarihsel ortalama<\/td><\/tr><tr><td>B\u00fcy\u00fcme Arayan<\/td><td>Pipeline kataliz\u00f6r konumland\u0131rmas\u0131<\/td><td>Faz 3 veri a\u00e7\u0131klamalar\u0131<\/td><\/tr><\/tbody><\/table><\/div><\/div>[cta_button text=\"\"]<div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Sonu\u00e7: Pfizer \u0130yi Bir Hisse Senedi mi?<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>\"Pfizer \u015fu anda iyi bir hisse senedi mi\" diye soran yat\u0131r\u0131mc\u0131lar i\u00e7in veriler, gelir avantajlar\u0131 ile cazip bir de\u011fer f\u0131rsat\u0131 sunuyor. \u015eirketin %4.7 temett\u00fc getirisi, sekt\u00f6r ortalamas\u0131n\u0131n alt\u0131nda olan 12.3x F\/K oran\u0131 ve 15.4 milyar dolar nakit pozisyonu, a\u015fa\u011f\u0131 y\u00f6nl\u00fc koruma sa\u011flarken, geni\u015fleyen onkoloji ve nadir hastal\u0131k pipeline'\u0131 b\u00fcy\u00fcme potansiyeli sunuyor.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pocket Option kullanarak ila\u00e7 hisse senedi analizi yapan yat\u0131r\u0131mc\u0131lar, elranatamab (2025 2. \u00e7eyrek) ve danuglipron (2025 3. \u00e7eyrek) i\u00e7in yakla\u015fan klinik veri a\u00e7\u0131klamalar\u0131n\u0131 potansiyel olumlu kataliz\u00f6rler olarak izlemelidir. Patent s\u00fcrelerinin dolmas\u0131na y\u00f6nelik stratejik hamleler ve rakiplere g\u00f6re de\u011ferleme indirimi ile Pfizer, sa\u011fl\u0131k hizmetlerine maruz kalmak isteyen dengeli portf\u00f6yler i\u00e7in \u00e7ekici bir risk-getiri profili sunuyor.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pocket Option'\u0131n kapsaml\u0131 analiz ara\u00e7lar\u0131 ile bug\u00fcn ila\u00e7 yat\u0131r\u0131m\u0131 yolculu\u011funuza ba\u015flay\u0131n, Pfizer'\u0131n belirli yat\u0131r\u0131m hedefleriniz ve risk tolerans\u0131n\u0131zla uyumlu olup olmad\u0131\u011f\u0131n\u0131 belirlemenize yard\u0131mc\u0131 olun.<\/p><\/div>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Pfizer&#8217;\u0131n Finansal Sa\u011fl\u0131\u011f\u0131n\u0131 \u00c7\u00f6z\u00fcmleme: Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Anahtar Metrikler<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Yat\u0131r\u0131mc\u0131lar &#8220;Pfizer iyi bir hisse senedi mi&#8221; diye sordu\u011funda, \u015firketin sa\u011flam finansal temellerini incelemelidirler. Pfizer, en son raporlama d\u00f6nemine g\u00f6re 2.4x bor\u00e7-EBITDA oran\u0131 ve 15.4 milyar dolar nakit rezervi ile COVID-19 a\u015f\u0131 gelir art\u0131\u015f\u0131n\u0131n \u00f6tesinde finansal istikrar sergiliyor.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pfizer&#8217;\u0131n %4.7 temett\u00fc getirisi, %2.8 olan ila\u00e7 sekt\u00f6r\u00fc ortalamas\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde a\u015farak de\u011fer yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in \u00e7ekici bir giri\u015f noktas\u0131 olu\u015fturuyor. 12 y\u0131l \u00fcst \u00fcste temett\u00fcleri art\u0131ran Pfizer, piyasa dalgalanmalar\u0131 s\u0131ras\u0131nda &#8220;Pfizer hissesi almal\u0131 m\u0131y\u0131m&#8221; diye d\u00fc\u015f\u00fcnenler i\u00e7in cazip nedenler sunuyor.<\/p>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>Finansal Metrik<\/th>\n<th>Pfizer Performans\u0131<\/th>\n<th>Sekt\u00f6r Ortalamas\u0131<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Temett\u00fc Getirisi<\/td>\n<td>%4.7<\/td>\n<td>%2.8<\/td>\n<\/tr>\n<tr>\n<td>F\/K Oran\u0131<\/td>\n<td>12.3<\/td>\n<td>16.8<\/td>\n<\/tr>\n<tr>\n<td>Bor\u00e7-EBITDA<\/td>\n<td>2.4x<\/td>\n<td>3.1x<\/td>\n<\/tr>\n<tr>\n<td>Nakit Rezervleri<\/td>\n<td>15.4 milyar dolar<\/td>\n<td>8.6 milyar dolar<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Pipeline Potansiyeli: Gelecek B\u00fcy\u00fcme Kataliz\u00f6rleri<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pfizer&#8217;\u0131n \u015fu anda iyi bir hisse senedi olup olmad\u0131\u011f\u0131n\u0131 belirlemede kritik bir fakt\u00f6r, \u00fcr\u00fcn pipeline&#8217;\u0131d\u0131r. Pfizer, 24&#8217;\u00fc ileri a\u015fama denemelerde olan 89 bile\u015fik geli\u015ftirmektedir. \u00c7oklu miyelom i\u00e7in elranatamab ve diyabet i\u00e7in danuglipron gibi anahtar adaylar, \u00e7ok milyar dolarl\u0131k pazarlar\u0131 hedefliyor.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pocket Option kullanarak hisse senedi analizi yapan yat\u0131r\u0131mc\u0131lar, Pfizer&#8217;\u0131n onkoloji portf\u00f6y\u00fcn\u00fc d\u00f6rt pazarlanm\u0131\u015f kanser tedavisi ile g\u00fc\u00e7lendiren Seagen&#8217;in 43 milyar dolarl\u0131k sat\u0131n al\u0131m\u0131n\u0131 not etmelidir. Bu stratejik hamle, 2027-2030 patent u\u00e7urumu s\u0131ras\u0131nda, mevcut gelirin %26&#8217;s\u0131n\u0131 temsil eden ila\u00e7lar\u0131n m\u00fcnhas\u0131rl\u0131\u011f\u0131n\u0131 kaybedece\u011fi d\u00f6nemi do\u011frudan ele al\u0131yor.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h3 class='po-article-page__title'>B\u00fcy\u00fcme Y\u00f6r\u00fcngesini Yeniden \u015eekillendiren Stratejik Sat\u0131n Al\u0131mlar<\/h3>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>Son Sat\u0131n Alma<\/th>\n<th>Terap\u00f6tik Odak<\/th>\n<th>Gelir Potansiyeli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Seagen (2023)<\/td>\n<td>Onkoloji<\/td>\n<td>2030&#8217;a kadar 10+ milyar dolar<\/td>\n<\/tr>\n<tr>\n<td>Arena Pharmaceuticals<\/td>\n<td>\u0130mm\u00fcnoloji<\/td>\n<td>2028&#8217;e kadar 3-5 milyar dolar<\/td>\n<\/tr>\n<tr>\n<td>ReViral<\/td>\n<td>Solunum Hastal\u0131\u011f\u0131<\/td>\n<td>2027&#8217;ye kadar 1-2 milyar dolar<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Ana Rakiplere Kar\u015f\u0131 Rekabet\u00e7i Konum<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pfizer&#8217;\u0131n Johnson &amp; Johnson, Merck ve Novartis&#8217;e kar\u015f\u0131 konumunu anlamak, Pfizer&#8217;\u0131n iyi bir hisse senedi olup olmad\u0131\u011f\u0131n\u0131 de\u011ferlendirirken \u00f6nemli bir ba\u011flam sa\u011flar. J&amp;J daha fazla \u00e7e\u015fitlilik sunarken ve Merck daha g\u00fc\u00e7l\u00fc son b\u00fcy\u00fcme oranlar\u0131 g\u00f6sterirken, Pfizer&#8217;\u0131n %22 onkoloji CAGR&#8217;si, %14 olan sekt\u00f6r ortalamas\u0131n\u0131 a\u015f\u0131yor.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pocket Option analiz ara\u00e7lar\u0131, Pfizer&#8217;\u0131n %19 i\u015fletme marj\u0131n\u0131n, %15 olan ila\u00e7 sekt\u00f6r\u00fc ortalamas\u0131n\u0131 a\u015ft\u0131\u011f\u0131n\u0131 ve geliri k\u00e2ra d\u00f6n\u00fc\u015ft\u00fcrmede verimlili\u011fi g\u00f6sterdi\u011fini ortaya koyuyor. &#8220;Pfizer hissesini satmal\u0131 m\u0131y\u0131m&#8221; diye soran yat\u0131r\u0131mc\u0131lar, \u015firketin 2008-2009 resesyonu s\u0131ras\u0131nda, daha geni\u015f piyasa %38 d\u00fc\u015ferken, istikrarl\u0131 gelir sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6z \u00f6n\u00fcnde bulundurmal\u0131d\u0131r.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Risk De\u011ferlendirmesi: Patent U\u00e7urumlar\u0131 ve Azaltma Stratejileri<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pfizer&#8217;\u0131n \u015fu anda iyi bir hisse senedi olup olmad\u0131\u011f\u0131n\u0131 d\u00fc\u015f\u00fcnenler i\u00e7in, Eliquis (5.6 milyar dolar gelir), Xtandi (1.2 milyar dolar) ve Ibrance (5.4 milyar dolar) i\u00e7in 2026-2029 patent s\u00fcrelerinin dolmas\u0131 \u00f6nemli zorluklar te\u015fkil ediyor. Ancak, Pfizer, 2011&#8217;deki Lipitor patent kayb\u0131n\u0131 (13 milyar dolar zirve sat\u0131\u015flar\u0131) maliyetleri %25 azaltarak ve 24 ay i\u00e7inde be\u015f yeni ila\u00e7 onay\u0131n\u0131 h\u0131zland\u0131rarak ba\u015far\u0131yla atlatt\u0131.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm article-content po-article-page__text'>\n<ul class='po-article-page-list'>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Pipeline de\u011fi\u015ftirme potansiyeli: 2026&#8217;dan \u00f6nce planlanan 15 yeni ila\u00e7 ba\u015fvurusu<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>2025-2027 i\u00e7in stratejik sat\u0131n al\u0131mlar i\u00e7in 25 milyar dolar b\u00fct\u00e7e<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Asya-Pasifik&#8217;te co\u011frafi geni\u015fleme, geli\u015fmekte olan pazarlarda %18 b\u00fcy\u00fcme hedefliyor<\/li>\n<\/ul>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>Risk Fakt\u00f6r\u00fc<\/th>\n<th>Potansiyel Gelir Etkisi<\/th>\n<th>Azaltma Stratejisi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Eliquis Patenti (2026)<\/td>\n<td>Y\u0131ll\u0131k -5.6 milyar dolar<\/td>\n<td>Oral PCSK9 lansman\u0131 (2025)<\/td>\n<\/tr>\n<tr>\n<td>ABD Fiyatland\u0131rma Mevzuat\u0131<\/td>\n<td>%8 marj s\u0131k\u0131\u015fmas\u0131<\/td>\n<td>3 milyar dolarl\u0131k maliyet yeniden yap\u0131land\u0131rma program\u0131<\/td>\n<\/tr>\n<tr>\n<td>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/td>\n<td>Programa g\u00f6re de\u011fi\u015fir<\/td>\n<td>Geli\u015ftirilmekte olan 89 bile\u015fik<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>De\u011ferleme Analizi: Fiyat vs. Potansiyel<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Mevcut de\u011ferleme metrikleri, Pfizer&#8217;\u0131n 12.3x F\/K oran\u0131nda i\u015flem g\u00f6rd\u00fc\u011f\u00fcn\u00fc, hem 10 y\u0131ll\u0131k tarihsel ortalamas\u0131n\u0131n (14.8x) hem de ila\u00e7 sekt\u00f6r\u00fc ortalamas\u0131n\u0131n (16.8x) alt\u0131nda oldu\u011funu g\u00f6steriyor. Yat\u0131r\u0131mc\u0131lar &#8220;Pfizer iyi bir hisse mi&#8221; diye Pocket Option kullanarak de\u011ferlendirdi\u011finde, bu indirim, pipeline varl\u0131klar\u0131n\u0131n beklenen sonu\u00e7lar\u0131 vermesi durumunda potansiyel bir d\u00fc\u015f\u00fck de\u011ferleme oldu\u011funu g\u00f6steriyor.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>15.4 milyar dolar nakit ve y\u0131l\u0131n tamam\u0131 i\u00e7in projeksiyon edilen 23 milyar dolar serbest nakit ak\u0131\u015f\u0131 ile Pfizer, hem %4.7 temett\u00fc getirisini hem de planlanan 25 milyar dolarl\u0131k stratejik sat\u0131n al\u0131mlar\u0131 desteklemek i\u00e7in finansal esnekli\u011fe sahiptir. Bu g\u00fc\u00e7l\u00fc sermaye pozisyonu, hissedar de\u011feri yaratmak i\u00e7in birden fazla yol sunar.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Yat\u0131r\u0131m Stratejisi: Farkl\u0131 Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in \u00d6zelle\u015ftirilmi\u015f Yakla\u015f\u0131mlar<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>&#8220;Pfizer hissesi almal\u0131 m\u0131y\u0131m&#8221; sorusunun yan\u0131t\u0131, yat\u0131r\u0131m hedeflerinize ba\u011fl\u0131 olarak farkl\u0131l\u0131k g\u00f6sterir. Gelir yat\u0131r\u0131mc\u0131lar\u0131, Pfizer&#8217;\u0131n %4.7 temett\u00fc getirisi ve %53 \u00f6deme oran\u0131ndan faydalanarak temett\u00fc s\u00fcrd\u00fcr\u00fclebilirli\u011fini \u00f6nerir. B\u00fcy\u00fcme odakl\u0131 yat\u0131r\u0131mc\u0131lar, \u00f6n\u00fcm\u00fczdeki pipeline kataliz\u00f6rlerine, \u00f6n\u00fcm\u00fczdeki 18 ayda planlanan 5 ila\u00e7 lansman\u0131na odaklanmal\u0131d\u0131r.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pocket Option, yat\u0131r\u0131mc\u0131lar\u0131n Pfizer pozisyonlar\u0131n\u0131 risk toleranslar\u0131 ve zaman ufuklar\u0131 ile uyumlu hale getirmelerine olanak tan\u0131yan ara\u00e7lar sunar. Muhafazakar yat\u0131r\u0131mc\u0131lar, Pfizer&#8217;\u0131n pipeline ge\u00e7i\u015fi boyunca dolar-maliyet ortalamas\u0131 yapmay\u0131 d\u00fc\u015f\u00fcnebilirken, daha y\u00fcksek risk tolerans\u0131na sahip olanlar, b\u00fcy\u00fck klinik veri a\u00e7\u0131klamalar\u0131 \u00f6ncesinde stratejik olarak pozisyonlar\u0131n\u0131 art\u0131rabilirler.<\/p>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>Yat\u0131r\u0131mc\u0131 Profili<\/th>\n<th>Optimal Pfizer Stratejisi<\/th>\n<th>Anahtar Performans G\u00f6stergesi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Gelir Odakl\u0131<\/td>\n<td>Uzun vadeli tutma<\/td>\n<td>Temett\u00fc b\u00fcy\u00fcme oran\u0131 (%5.3)<\/td>\n<\/tr>\n<tr>\n<td>De\u011fer Odakl\u0131<\/td>\n<td>Zay\u0131fl\u0131kta biriktirme<\/td>\n<td>F\/K vs. tarihsel ortalama<\/td>\n<\/tr>\n<tr>\n<td>B\u00fcy\u00fcme Arayan<\/td>\n<td>Pipeline kataliz\u00f6r konumland\u0131rmas\u0131<\/td>\n<td>Faz 3 veri a\u00e7\u0131klamalar\u0131<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n    <div class=\"po-container po-container_width_article\">\n        <a href=\"\/en\/quick-start\/\" class=\"po-line-banner po-article-page__line-banner\">\n            <svg class=\"svg-image po-line-banner__logo\" fill=\"currentColor\" width=\"auto\" height=\"auto\"\n                 aria-hidden=\"true\">\n                <use href=\"#svg-img-logo-white\"><\/use>\n            <\/svg>\n            <span class=\"po-line-banner__btn\"><\/span>\n        <\/a>\n    <\/div>\n    \n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Sonu\u00e7: Pfizer \u0130yi Bir Hisse Senedi mi?<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>&#8220;Pfizer \u015fu anda iyi bir hisse senedi mi&#8221; diye soran yat\u0131r\u0131mc\u0131lar i\u00e7in veriler, gelir avantajlar\u0131 ile cazip bir de\u011fer f\u0131rsat\u0131 sunuyor. \u015eirketin %4.7 temett\u00fc getirisi, sekt\u00f6r ortalamas\u0131n\u0131n alt\u0131nda olan 12.3x F\/K oran\u0131 ve 15.4 milyar dolar nakit pozisyonu, a\u015fa\u011f\u0131 y\u00f6nl\u00fc koruma sa\u011flarken, geni\u015fleyen onkoloji ve nadir hastal\u0131k pipeline&#8217;\u0131 b\u00fcy\u00fcme potansiyeli sunuyor.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pocket Option kullanarak ila\u00e7 hisse senedi analizi yapan yat\u0131r\u0131mc\u0131lar, elranatamab (2025 2. \u00e7eyrek) ve danuglipron (2025 3. \u00e7eyrek) i\u00e7in yakla\u015fan klinik veri a\u00e7\u0131klamalar\u0131n\u0131 potansiyel olumlu kataliz\u00f6rler olarak izlemelidir. Patent s\u00fcrelerinin dolmas\u0131na y\u00f6nelik stratejik hamleler ve rakiplere g\u00f6re de\u011ferleme indirimi ile Pfizer, sa\u011fl\u0131k hizmetlerine maruz kalmak isteyen dengeli portf\u00f6yler i\u00e7in \u00e7ekici bir risk-getiri profili sunuyor.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pocket Option&#8217;\u0131n kapsaml\u0131 analiz ara\u00e7lar\u0131 ile bug\u00fcn ila\u00e7 yat\u0131r\u0131m\u0131 yolculu\u011funuza ba\u015flay\u0131n, Pfizer&#8217;\u0131n belirli yat\u0131r\u0131m hedefleriniz ve risk tolerans\u0131n\u0131zla uyumlu olup olmad\u0131\u011f\u0131n\u0131 belirlemenize yard\u0131mc\u0131 olun.<\/p>\n<\/div>\n"},"faq":[{"question":"Pfizer, temett\u00fc yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in iyi bir hisse senedi mi?","answer":"Pfizer, ila\u00e7 sekt\u00f6r\u00fc ortalamas\u0131 olan %2,8'e k\u0131yasla %4,7 temett\u00fc getirisi sunuyor ve 12 y\u0131l \u00fcst \u00fcste temett\u00fcleri art\u0131rd\u0131. \u015eirketin %53'l\u00fck \u00f6deme oran\u0131 ve 23 milyar dolarl\u0131k y\u0131ll\u0131k projeksiyonlu serbest nakit ak\u0131\u015f\u0131, temett\u00fc s\u00fcrd\u00fcr\u00fclebilirli\u011fini g\u00fc\u00e7l\u00fc bir \u015fekilde destekliyor."},{"question":"Patent s\u00fcrelerinin dolmas\u0131 Pfizer'\u0131n hisse performans\u0131n\u0131 nas\u0131l etkileyebilir?","answer":"Eliquis (5,6 milyar $), Xtandi (1,2 milyar $) ve Ibrance (5,4 milyar $) 2026-2029 y\u0131llar\u0131 aras\u0131nda patent s\u00fcrelerinin dolmas\u0131yla kar\u015f\u0131 kar\u015f\u0131ya, bu da geliri %26 oran\u0131nda azaltabilir. Pfizer, 2026'dan \u00f6nce 15 yeni ila\u00e7 ba\u015fvurusu ve 43 milyar dolarl\u0131k Seagen sat\u0131n al\u0131m\u0131 gibi stratejik sat\u0131n almalarla buna kar\u015f\u0131 koyuyor."},{"question":"Pfizer hisse senedi, boru hatt\u0131 potansiyeline dayanarak sat\u0131n al\u0131nmal\u0131 m\u0131?","answer":"Pfizer, 24'\u00fc ileri a\u015fama denemelerde olmak \u00fczere geli\u015ftirilmekte olan 89 bile\u015fi\u011fe sahiptir. Bunlar aras\u0131nda \u00e7oklu miyelom i\u00e7in potansiyel bir blockbuster olan elranatamab ve diyabet i\u00e7in danuglipron bulunmaktad\u0131r. 2025'in ikinci ve \u00fc\u00e7\u00fcnc\u00fc \u00e7eyre\u011findeki \u00f6nemli veri a\u00e7\u0131klamalar\u0131, hisse performans\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilir."},{"question":"Pfizer'in daha k\u00fc\u00e7\u00fck ila\u00e7 \u015firketlerine g\u00f6re hangi avantajlar\u0131 var?","answer":"Pfizer'\u0131n 15,4 milyar dolarl\u0131k nakit rezervleri, %19 i\u015fletme marj\u0131 (sekt\u00f6r ortalamas\u0131 %15) ve k\u00fcresel ticari altyap\u0131s\u0131 \u00f6nemli rekabet avantajlar\u0131 yaratmaktad\u0131r. \u015eirketin d\u00fczenleyici uzmanl\u0131\u011f\u0131 ve \u00fcretim \u00f6l\u00e7e\u011fi, yeni ila\u00e7lar\u0131 daha k\u00fc\u00e7\u00fck rakiplerine g\u00f6re daha verimli bir \u015fekilde piyasaya s\u00fcrmesine olanak tan\u0131r."},{"question":"Sa\u011fl\u0131k d\u00fczenlemeleri de\u011fi\u015firse Pfizer hisselerini satmal\u0131 m\u0131y\u0131m?","answer":"Son ABD ila\u00e7 fiyatland\u0131rma mevzuat\u0131n\u0131n Pfizer'in marjlar\u0131n\u0131 yakla\u015f\u0131k %8 oran\u0131nda etkilemesi bekleniyor, ancak \u015firket bu bask\u0131lar\u0131 dengelemek i\u00e7in 3 milyar dolarl\u0131k bir maliyet yeniden yap\u0131land\u0131rma program\u0131 uygulamaya koydu. Pfizer'in k\u00fcresel \u00e7e\u015fitlendirmesi, tek bir d\u00fczenleyici pazar\u0131n toplam gelirin %40'\u0131ndan fazlas\u0131n\u0131 temsil etmedi\u011fi anlam\u0131na geliyor."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Pfizer, temett\u00fc yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in iyi bir hisse senedi mi?","answer":"Pfizer, ila\u00e7 sekt\u00f6r\u00fc ortalamas\u0131 olan %2,8'e k\u0131yasla %4,7 temett\u00fc getirisi sunuyor ve 12 y\u0131l \u00fcst \u00fcste temett\u00fcleri art\u0131rd\u0131. \u015eirketin %53'l\u00fck \u00f6deme oran\u0131 ve 23 milyar dolarl\u0131k y\u0131ll\u0131k projeksiyonlu serbest nakit ak\u0131\u015f\u0131, temett\u00fc s\u00fcrd\u00fcr\u00fclebilirli\u011fini g\u00fc\u00e7l\u00fc bir \u015fekilde destekliyor."},{"question":"Patent s\u00fcrelerinin dolmas\u0131 Pfizer'\u0131n hisse performans\u0131n\u0131 nas\u0131l etkileyebilir?","answer":"Eliquis (5,6 milyar $), Xtandi (1,2 milyar $) ve Ibrance (5,4 milyar $) 2026-2029 y\u0131llar\u0131 aras\u0131nda patent s\u00fcrelerinin dolmas\u0131yla kar\u015f\u0131 kar\u015f\u0131ya, bu da geliri %26 oran\u0131nda azaltabilir. Pfizer, 2026'dan \u00f6nce 15 yeni ila\u00e7 ba\u015fvurusu ve 43 milyar dolarl\u0131k Seagen sat\u0131n al\u0131m\u0131 gibi stratejik sat\u0131n almalarla buna kar\u015f\u0131 koyuyor."},{"question":"Pfizer hisse senedi, boru hatt\u0131 potansiyeline dayanarak sat\u0131n al\u0131nmal\u0131 m\u0131?","answer":"Pfizer, 24'\u00fc ileri a\u015fama denemelerde olmak \u00fczere geli\u015ftirilmekte olan 89 bile\u015fi\u011fe sahiptir. Bunlar aras\u0131nda \u00e7oklu miyelom i\u00e7in potansiyel bir blockbuster olan elranatamab ve diyabet i\u00e7in danuglipron bulunmaktad\u0131r. 2025'in ikinci ve \u00fc\u00e7\u00fcnc\u00fc \u00e7eyre\u011findeki \u00f6nemli veri a\u00e7\u0131klamalar\u0131, hisse performans\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilir."},{"question":"Pfizer'in daha k\u00fc\u00e7\u00fck ila\u00e7 \u015firketlerine g\u00f6re hangi avantajlar\u0131 var?","answer":"Pfizer'\u0131n 15,4 milyar dolarl\u0131k nakit rezervleri, %19 i\u015fletme marj\u0131 (sekt\u00f6r ortalamas\u0131 %15) ve k\u00fcresel ticari altyap\u0131s\u0131 \u00f6nemli rekabet avantajlar\u0131 yaratmaktad\u0131r. \u015eirketin d\u00fczenleyici uzmanl\u0131\u011f\u0131 ve \u00fcretim \u00f6l\u00e7e\u011fi, yeni ila\u00e7lar\u0131 daha k\u00fc\u00e7\u00fck rakiplerine g\u00f6re daha verimli bir \u015fekilde piyasaya s\u00fcrmesine olanak tan\u0131r."},{"question":"Sa\u011fl\u0131k d\u00fczenlemeleri de\u011fi\u015firse Pfizer hisselerini satmal\u0131 m\u0131y\u0131m?","answer":"Son ABD ila\u00e7 fiyatland\u0131rma mevzuat\u0131n\u0131n Pfizer'in marjlar\u0131n\u0131 yakla\u015f\u0131k %8 oran\u0131nda etkilemesi bekleniyor, ancak \u015firket bu bask\u0131lar\u0131 dengelemek i\u00e7in 3 milyar dolarl\u0131k bir maliyet yeniden yap\u0131land\u0131rma program\u0131 uygulamaya koydu. Pfizer'in k\u00fcresel \u00e7e\u015fitlendirmesi, tek bir d\u00fczenleyici pazar\u0131n toplam gelirin %40'\u0131ndan fazlas\u0131n\u0131 temsil etmedi\u011fi anlam\u0131na geliyor."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer Hisse Senedi Almak \u0130\u00e7in \u0130yi mi: Yat\u0131r\u0131m G\u00f6r\u00fcn\u00fcm\u00fc<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Hisse Senedi Almak \u0130\u00e7in \u0130yi mi: Yat\u0131r\u0131m G\u00f6r\u00fcn\u00fcm\u00fc\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-19T11:47:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Sell-Put-Options-Cash-Secured-Puts-on-Stocks.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1840\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Tatiana OK\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatiana OK\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/\"},\"author\":{\"name\":\"Tatiana OK\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"headline\":\"Pfizer Hisse Senedi Almak \u0130\u00e7in \u0130yi mi: Yat\u0131r\u0131m G\u00f6r\u00fcn\u00fcm\u00fc\",\"datePublished\":\"2025-07-19T11:47:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/\"},\"wordCount\":14,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Sell-Put-Options-Cash-Secured-Puts-on-Stocks.webp\",\"keywords\":[\"investment\",\"stock\",\"strategy\"],\"articleSection\":[\"Learning\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/\",\"name\":\"Pfizer Hisse Senedi Almak \u0130\u00e7in \u0130yi mi: Yat\u0131r\u0131m G\u00f6r\u00fcn\u00fcm\u00fc\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Sell-Put-Options-Cash-Secured-Puts-on-Stocks.webp\",\"datePublished\":\"2025-07-19T11:47:48+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Sell-Put-Options-Cash-Secured-Puts-on-Stocks.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Sell-Put-Options-Cash-Secured-Puts-on-Stocks.webp\",\"width\":1840,\"height\":700},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Hisse Senedi Almak \u0130\u00e7in \u0130yi mi: Yat\u0131r\u0131m G\u00f6r\u00fcn\u00fcm\u00fc\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\",\"name\":\"Tatiana OK\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"caption\":\"Tatiana OK\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/tatiana\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Hisse Senedi Almak \u0130\u00e7in \u0130yi mi: Yat\u0131r\u0131m G\u00f6r\u00fcn\u00fcm\u00fc","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/","og_locale":"tr_TR","og_type":"article","og_title":"Pfizer Hisse Senedi Almak \u0130\u00e7in \u0130yi mi: Yat\u0131r\u0131m G\u00f6r\u00fcn\u00fcm\u00fc","og_url":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/","og_site_name":"Pocket Option blog","article_published_time":"2025-07-19T11:47:48+00:00","og_image":[{"width":1840,"height":700,"url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Sell-Put-Options-Cash-Secured-Puts-on-Stocks.webp","type":"image\/webp"}],"author":"Tatiana OK","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Tatiana OK"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/"},"author":{"name":"Tatiana OK","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"headline":"Pfizer Hisse Senedi Almak \u0130\u00e7in \u0130yi mi: Yat\u0131r\u0131m G\u00f6r\u00fcn\u00fcm\u00fc","datePublished":"2025-07-19T11:47:48+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/"},"wordCount":14,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Sell-Put-Options-Cash-Secured-Puts-on-Stocks.webp","keywords":["investment","stock","strategy"],"articleSection":["Learning"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/","url":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/","name":"Pfizer Hisse Senedi Almak \u0130\u00e7in \u0130yi mi: Yat\u0131r\u0131m G\u00f6r\u00fcn\u00fcm\u00fc","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Sell-Put-Options-Cash-Secured-Puts-on-Stocks.webp","datePublished":"2025-07-19T11:47:48+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Sell-Put-Options-Cash-Secured-Puts-on-Stocks.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Sell-Put-Options-Cash-Secured-Puts-on-Stocks.webp","width":1840,"height":700},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Pfizer Hisse Senedi Almak \u0130\u00e7in \u0130yi mi: Yat\u0131r\u0131m G\u00f6r\u00fcn\u00fcm\u00fc"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d","name":"Tatiana OK","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","caption":"Tatiana OK"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/tatiana\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":315921,"slug":"is-pfizer-a-good-stock-to-buy","post_title":"Pfizer c\u00f3 ph\u1ea3i l\u00e0 c\u1ed5 phi\u1ebfu t\u1ed1t \u0111\u1ec3 mua: Tri\u1ec3n v\u1ecdng \u0111\u1ea7u t\u01b0","href":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/"},"pt_AA":{"locale":"pt_AA","id":315916,"slug":"is-pfizer-a-good-stock-to-buy","post_title":"A\u00e7\u00f5es da Pfizer s\u00e3o uma Boa Compra: Perspectiva de Investimento","href":"https:\/\/pocketoption.com\/blog\/pt\/knowledge-base\/learning\/is-pfizer-a-good-stock-to-buy\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/315919","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=315919"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/315919\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/307480"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=315919"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=315919"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=315919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}